Literature DB >> 26099430

Pure versus combined Merkel cell carcinomas: immunohistochemical evaluation of cellular proteins (p53, Bcl-2, and c-kit) reveals significant overexpression of p53 in combined tumors.

Jonathan H Lai1, Kirsten E Fleming2, Thai Yen Ly2, Sylvia Pasternak2, Marek Godlewski3, Steve Doucette4, Noreen M Walsh5.   

Abstract

Merkel cell polyomavirus is of oncogenic significance in approximately 80% of Merkel cell carcinomas. Morphological subcategories of the tumor differ in regard to viral status, the rare combined type being uniformly virus negative and the predominant pure type being mainly virus positive. Indications that different biological subsets of the tumor exist led us to explore this diversity. In an Eastern Canadian cohort of cases (75 patients; mean age, 76 years [range, 43-91]; male/female ratio, 43:32; 51 [68%] pure and 24 [34%] combined tumors), we semiquantitatively compared the immunohistochemical expression of 3 cellular proteins (p53, Bcl-2, and c-kit) in pure versus combined groups. Viral status was known in a subset of cases. The significant overexpression of p53 in the combined group (mean [SD], 153.8 [117.8] versus 121.6 [77.9]; P = .01) and the increased epidermal expression of this protein (p53 patches) in the same group lend credence to a primary etiologic role for sun damage in these cases. Expression of Bcl-2 and c-kit did not differ significantly between the 2 morphological groups. A relative increase in c-kit expression was significantly associated with a virus-negative status (median [interquartile range], 100 [60-115] versus 70 [0-100]; P = .03). Emerging data reveal divergent biological pathways in Merkel cell carcinoma, each with a characteristic immunohistochemical profile. Virus-positive tumors (all pure) exhibit high retinoblastoma protein and low p53 expression, whereas virus-negative cases (few pure and all combined) show high p53 and relatively high c-kit expression. The potential biological implications of this dichotomy call for consistent stratification of these tumors in future studies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bcl-2; CD117 (c-kit); Combined Merkel cell carcinoma; Cutaneous neuroendocrine carcinoma; Merkel cell carcinoma; Pure Merkel cell carcinoma; p53

Mesh:

Substances:

Year:  2015        PMID: 26099430     DOI: 10.1016/j.humpath.2015.05.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

Review 1.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

Review 2.  Merkel Cell Carcinoma.

Authors:  Melissa Pulitzer
Journal:  Surg Pathol Clin       Date:  2017-03-14

3.  Detection of the Merkel cell polyomavirus in the neuroendocrine component of combined Merkel cell carcinoma.

Authors:  Thibault Kervarrec; Mahtab Samimi; Pauline Gaboriaud; Tarik Gheit; Agnès Beby-Defaux; Roland Houben; David Schrama; Gaëlle Fromont; Massimo Tommasino; Yannick Le Corre; Eva Hainaut-Wierzbicka; Francois Aubin; Guido Bens; Hervé Maillard; Adeline Furudoï; Patrick Michenet; Antoine Touzé; Serge Guyétant
Journal:  Virchows Arch       Date:  2018-03-28       Impact factor: 4.064

4.  RB1-deficient squamous cell carcinoma: the proposed source of combined Merkel cell carcinoma.

Authors:  Ryan C DeCoste; Noreen M Walsh; Daniel Gaston; Thai Yen Ly; Sylvia Pasternak; Sam Cutler; Mat Nightingale; Michael D Carter
Journal:  Mod Pathol       Date:  2022-09-08       Impact factor: 8.209

Review 5.  Merkel cell carcinoma.

Authors:  Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem
Journal:  Nat Rev Dis Primers       Date:  2017-10-26       Impact factor: 52.329

6.  Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Christopher K Bichakjian; Thomas Olencki; Sumaira Z Aasi; Murad Alam; James S Andersen; Rachel Blitzblau; Glen M Bowen; Carlo M Contreras; Gregory A Daniels; Roy Decker; Jeffrey M Farma; Kris Fisher; Brian Gastman; Karthik Ghosh; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Manisha Loss; Daniel D Lydiatt; Jane Messina; Kishwer S Nehal; Paul Nghiem; Igor Puzanov; Chrysalyne D Schmults; Ashok R Shaha; Valencia Thomas; Yaohui G Xu; John A Zic; Karin G Hoffmann; Anita M Engh
Journal:  J Natl Compr Canc Netw       Date:  2018-06       Impact factor: 12.693

7.  Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth in vitro.

Authors:  Emil Chteinberg; Suzan Wetzels; Wouter Gerritsen; Lieve Temmerman; Joost van den Oord; Erik Biessen; Anna Kordelia Kurz; Véronique Winnepenninckx; Martin Zenke; Ernst-Jan Speel; Axel Zur Hausen
Journal:  Ther Adv Med Oncol       Date:  2020-12-14       Impact factor: 8.168

8.  Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer.

Authors:  Yanli Luo; Wentao Huang; Huizhen Zhang; Guang Liu
Journal:  Oncol Lett       Date:  2018-02-22       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.